Escherichia coli (E. coli) Nissle (EcN) 1917 is a non-pathogenic Gram-negative strain used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and IBD, in particular Ulcerative colitis(UC). It was isolated by Prof. Alfred Nissle from Freiburg, Germany, in 1917 from the intestinal microflora of a young soldier. Using this E. coli strain Prof. Nissle developed the probiotic drug Mutaflor® and introduced it into medical practice in the same year. It exhibits a semi-rough lipopolysaccharide (LPS) phenotype and serum sensitivity and does not produce known toxins. EcN has an intestinal anti-inflammatory effect. It has direct antimicrobial effects: it inhibits EHEC (E. coli EDL933) colonization in animal models. This is very important in the formation of biofilm, adherence to epithelial cells and persistence in infant mouse colonization. E. coli strain Nissle 1917 does not possess any antibiotic resistance plasmids Mutaflor A bacterium becomes a medicinal product The discovery and development of ­Mutaflor goes back to Professor Alfred Nissle (1874–1965) from Freiburg. Efficacy in defined indications evidenced by controlled clinical studies Mutaflor is available as capsules, in three pack sizes Mutaflor Suspension is bottled in single-dose containers, available in five pack sizes

1. Escherichia coli (E. coli) Nissle (EcN) 1917
Presented By :- Sunil Meena
M. Tech. ( Dairy Technology ))

2. INTRODUCTION
• Escherichia coli (E. coli) Nissle (EcN) 1917 is a non-pathogenic Gram-negative strain
used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular
disease and IBD, in particular Ulcerative colitis(UC).
• It was isolated by Prof. Alfred Nissle from Freiburg, Germany, in 1917 from the intestinal
microflora of a young soldier.
• Using this E. coli strain Prof. Nissle developed the probiotic drug Mutaflor® and
introduced it into medical practice in the same year.

3. • It exhibits a semi-rough lipopolysaccharide (LPS) phenotype and serum sensitivity and
does not produce known toxins.
• EcN has an intestinal anti-inflammatory effect.
• It has direct antimicrobial effects: it inhibits EHEC (E. coli EDL933) colonization in animal
models.
• This is very important in the formation of biofilm, adherence to epithelial cells and
persistence in infant mouse colonization.
• E. coli strain Nissle 1917 does not possess any antibiotic resistance plasmids

4. Mutaflor
• A bacterium becomes a medicinal product
• The discovery and development of Mutaflor goes back to Professor
Alfred Nissle (1874–1965) from Freiburg.
• Efficacy in defined indications evidenced by controlled clinical studies
• Mutaflor is available as capsules, in three pack sizes
• Mutaflor Suspension is bottled in single-dose containers, available in
five pack sizes

5. Mechanism of action
• Suppression of growth and colonization of undesired microorganisms
• Contribution to optimizing the intestinal milieu and luminal metabolism
• Communication with the intestinal epithelium
• Colonization ability

6. Product quality
• Microbiological purity
• Defined number of viable cells
• Exact identification and differentiation from closely related
microorganisms
• Viability in the gastrointestinal tract

7. Safety
• Non-pathogenicity
• Genetic stability
Mutaflor – Therapeutic indications
• Chronic constipation
• Ulcerative colitis in the remission stage

8. Mutaflor Suspension – therapeutic indications
• Diarrhea in infants, toddlers and children (also under under tube feeding)
• Colonization prophylaxis in premature and full-term infants
• Enhancement of postnatal immune competence in premature and full-term
infants

9. Storage Information
• The probiotic medicinal product Mutaflor contains viable bacteria in a high
concentration. For this reason, it should be stored in a refrigerator at a
temperature ranging between +2° C and +8° C. An interruption of chilling for
a few days will have normally no influence on the number of viable cells.
• In case of a prolonged heat exposure, however, the bacterial cells will to some
extent lose their viability. No toxic substances will be develop.

10. 10